Thermo Fisher Scientific Inc (TMO) — closed signal from June 24, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on September 22, 2026 — +35% at the close.
Predicted vs. what happened
What happened
Reached its target in 29 days.
The thesis — published June 24, 2026
Thermo Fisher is a steady healthcare company rather than a fast-growing momentum name. Sales and profit trends have been reliable, and demand for its lab tools could rise as life-science firms adopt AI tools, run more decentralized trials, and expand clinical research. The main downsides are weak price momentum and relatively high debt. This setup favors resilience over rapid gains in the next 0-3 months.
Primary drivers
- AI use in life sciences should lift demand for lab tools
- Healthcare status helps performance in uncertain markets
- Reliable earnings reduce valuation swings
- Exposure to trials and bioproduction widens customer demand
How it played out
TMO: target reached in 29 days, peak gain was 36%
Lyra published TMO at $487.82 with an expected gain of 16% and a $565.87 target. The thesis pointed to demand for lab tools from greater use of artificial intelligence in life sciences, healthcare resilience, reliable earnings, and exposure to clinical trials and bioproduction.
The target was reached in 29 days. TMO later peaked at $663.57 on September 17, a 36% gain inside the window. It ended the window at $658.52, still above the target and close to the peak. The published thesis played out and exceeded its expected gain.
What happened during the window
On July 23, 2026, Thermo Fisher reported second-quarter revenue of $11.99 billion, up 10%, and adjusted earnings per share of $6.03, up 13%. On August 12, 2026, the company completed the sale of its microbiology business to Astorg for about $1.075 billion.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.